Dapiglutide dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Dapiglutide is the only drug in weight-loss testing that pairs GLP-1 with GLP-2. Its first test missed. In 54 people over 12 weeks, it took off 2.1 percent more weight than a dummy injection, a gap chance could explain.
Evidence grade for Dapiglutide: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, 54 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 54
- Human studies
- 1
- Found nothing
- 1
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 54 people given it
No first-hand reports gathered yet. That is a gap in what we have collected, not a finding that nothing has been reported.
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Dapiglutide is a weekly shot that works on two gut hormone signals, GLP-1 and GLP-2. GLP-1 cuts appetite. GLP-2 helps the gut lining grow and seal up. The idea is weight loss plus a calmer, less leaky gut. Zealand Pharma makes it. It is not approved.
What people take it for
- Weight loss.
- A healthier, less leaky gut.
- Less swelling in the gut.
What studies in people showed
There is one small study, in 54 adults with obesity in Denmark, over 12 weeks. Nobody changed their diet or exercise. The higher dose took off 2.1 percent more body weight than a dummy shot. That gap was small enough that chance could explain it. So the study missed its goal. The researchers think the doses may have been too low. The gut claim has not been tested in people at all. It comes from mice with part of their bowel removed.
What people report
Reports, not study results
The good
- Nobody in the study quit because of a side effect caused by the drug.
The bad
- Less appetite and nausea were the common side effects.
- Weight loss was too small to count as a real result.
Where these come from: These come from the study on this page. We have not collected user reports on this one yet.
My bottom line
A new idea with no win yet. In my opinion, the gut claim is a mouse result until someone tests it in people. There is nothing here to act on.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Dapiglutide has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Feeling less hungry54 people · 1 study · 1 found nothing
35 of the 36 indexed goals have no study of any kind behind Dapiglutide
No study in people, animals or cells on this page reports a result for these. That does not prove Dapiglutide does nothing for them. It does mean anything you have heard about Dapiglutide and one of these did not come from a study cited here.
Show full evidence
What is Dapiglutide?
Dapiglutide is the only drug in weight-loss testing that pairs GLP-1 with GLP-2. Its first test missed. In 54 people over 12 weeks, it took off 2.1 percent more weight than a dummy injection, a gap chance could explain.
This is a truly new idea with a negative result. This site exists to report that kind of thing properly.
Every other two-in-one drug here pairs GLP-1 with GIP, glucagon or amylin. Dapiglutide pairs it with GLP-2, a hormone whose job is the gut lining, not appetite or blood sugar. The idea is that GLP-2 tightens the gut wall and calms swelling. So a drug that hits both might bring weight loss plus a calmer gut.
The 12-week first test in 54 adults with obesity did not show the weight effect. The 6 mg dose took off 2.1 percent more body weight than a dummy injection. The likely range ran from 4.3 percent more to 0.2 percent less, so chance could explain it. The researchers said the gap was not large enough to count. They think higher doses in bigger, longer studies are worth testing.
How does Dapiglutide work?
Dapiglutide, from Zealand Pharma, acts on two hormone receptors: GLP-1 and GLP-2. The GLP-1 part cuts appetite. The GLP-2 part acts on the lining of the gut. It helps the lining grow and seal up. That is how a related drug, teduglutide, got approved for short bowel syndrome. The idea behind pairing them is that a leaky, inflamed gut adds to metabolic disease. Fixing the gut wall while cutting appetite might do more than cutting appetite alone. No one has tested that idea against a real measure of swelling in people.
What have studies in people found about Dapiglutide?
One 12-week first test in 54 people, against a dummy injection, and it missed its main goal. That is the whole human record. The GLP-2 idea rests on mouse work.
- 54 adults with obesity in three groups for 12 weeks. Nobody was asked to change diet or exercise. That is an unusually clean way to see what the drug alone does.
- Main goal missed: the 6 mg dose took off 2.1 percent more body weight than the dummy injection. The likely range ran from 4.3 percent more to 0.2 percent less.
- Safety was good. Nobody quit because of a side effect caused by the drug, and few people dropped out in any group.
- Less appetite and nausea were the common side effects. That shows the GLP-1 part is doing something.
- The authors back testing higher doses in bigger, longer studies rather than calling the idea dead.
What this does not tell you: 54 people over 12 weeks, at doses the researchers think may be too low. The likely range ran from 4.3 percent weight loss to 0.2 percent gain. That does not rule out a useful effect. So this study is unsettled, not proof the drug does nothing. Most important, the GLP-2 half of the idea, the gut wall and swelling, was not tested against any real health measure. The interesting part of the idea is still untested in people.
The state of the research
Dapiglutide earns a page precisely because it has not worked yet. Its approach is the only one of its kind in weight-loss development. The study that tested it is small, short and unsettled rather than final. The usual coverage loses both of those facts. It either ignores a missed goal or calls it a failure.
The honest reading is narrower. A 12-week study in 54 people at 4 and 6 mg found 2.1 percent weight loss, with a likely range that included zero. That is what a too-small early study looks like when a modest effect may exist. It is also what a study looks like when nothing is there. The gut wall claim, which is the new part, has not been measured against any real health result in people at all.
The evidence, in charts
Fig. 1a · how many people
54people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| EClinicalMedicine 2026 | 54 | 100% |
The whole total is one study of 54. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 1 more study in people gives no headcount and is not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
2 of 3 sources here are studies in people. The rest is not.
- Study in people · done in people267%
- Animal study · done in animals133%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2022 and 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- Peptide dual agonist. No mass asserted; no source loaded states one.
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Long-acting, dosed once weekly by subcutaneous injection. No specific half-life figure was resolved in the sources loaded.
No amino acid sequence is on file for Dapiglutide, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2026Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial
This early weight loss trial missed its target. 54 adults with obesity in Denmark were split by chance between two doses of dapiglutide and a dummy injection, weekly for three months. Nobody was asked to change their diet or exercise. The higher dose took off about two percent more body weight than the dummy, which is too small to separate from chance. The drug was tolerated well, with reduced appetite and nausea the usual complaints. Zealand Pharma funded it.
54 adults with obesity in Denmark, 63 percent women, mean bodyweight 101.3 kg and BMI 35.2, randomised 1:1:1 to dapiglutide 4 mg, 6 mg or placebo weekly for 12 weeks with no concurrent lifestyle intervention. Primary endpoint percentage bodyweight change. The 6 mg dose produced a mean change of minus 2.1 percent against placebo (95% CI minus 4.3 to 0.2, p = 0.076), not statistically significant. Safe and well tolerated, with reduced appetite and nausea the common adverse events and no discontinuations for drug-induced adverse events. Dropout 0 percent on placebo, 11 percent on 4 mg and 6 percent on 6 mg. Funded by an unrestricted grant from Zealand Pharma.
- Study in people2026A trial of dapiglutide in participants with obesity (DREAM)
This is the registry entry for the dapiglutide obesity trial above. It records that the trial ran and finished. The outcome is in the paper above, and the outcome was that the weight difference was too small to call.
The registry record for the trial above.
- Animal study2022Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel
In mice. In mice whose bowels had been shortened by surgery, dapiglutide eased the gut's failure to absorb enough food. This is where the GLP-2 half of the idea comes from. It was tested in mice after gut surgery, not in people with obesity.
Mouse. The origin of the GLP-2 half of the rationale, in a short bowel model where intestinal insufficiency was attenuated. This is the intestinal claim in its only tested form, and it was tested in mice with surgically shortened bowels rather than in people with obesity.
Where to buy Dapiglutide
No seller we track lists Dapiglutide yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has Dapiglutide been tested in people?
Yes. 54 people given it across 1 completed trial cited here, 1 of which found nothing. Dapiglutide is the only drug in weight-loss testing that pairs GLP-1 with GLP-2. Its first test missed. In 54 people over 12 weeks, it took off 2.1 percent more weight than a dummy injection, a gap chance could explain.
What is the Dapiglutide dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 54 people given it
Is Dapiglutide FDA-approved?
Investigational. Not approved anywhere.
Did dapiglutide work for weight loss?
Not in its first test. The 6 mg dose took off 2.1 percent more weight than a dummy injection over 12 weeks in 54 people. The likely range included zero, so chance could explain it. The researchers said it did not count as a real difference, and they suggest testing higher doses.
What does adding GLP-2 do?
In theory it repairs and thickens the gut lining and calms swelling in the gut. That is why a related drug, teduglutide, is approved for short bowel syndrome. Whether that helps people with obesity is the interesting question. This study did not measure gut swelling or the gut wall, so it is still untested in people.
Is the mechanism dead?
No, and it would be wrong to say so from this study. It had 54 people, ran 12 weeks, and used doses the company and researchers both think may be too low. What can be said is that it has no positive weight loss result yet.